Business Wire

Elliott Believes the Time is Now for NN Group

Share

Elliott Advisors (UK) Limited (“Elliott”), which advises funds that as at the date of this release collectively hold an interest in more than 3% of the share capital of NN Group N.V. (“NN Group” or the “Company”), today published a presentation making the case for its strong belief in NN Group’s uniquely compelling investment proposition and its significant value-creation potential. Elliott’s substantial investment reflects its conviction in the Company’s underlying value, which to date has been obscured, and the Company’s future prospects, which are not properly reflected in the Company’s current share price.

Elliott has significant experience as an investor in the insurance industry and has devoted considerable time and resources into understanding NN Group’s unique industry and financial characteristics. To assist us in this effort, we have partnered with Dieter Wemmer, an industry leader who brings more than 30 years of experience, having served as an executive at Allianz, Zurich Insurance Group, and elsewhere. Together, we have engaged privately with NN Group’s management over several months and we remain of the view that NN Group is worth far more than the market currently ascribes. The attractiveness of NN Group is rooted not only in the strength of its fundamental underlying business - exhibiting historically stable shareholder cash flows - but in its ability to successfully manage risk and deliver stable and sustainable results, irrespective of market volatility, including large changes in market interest rates and evolving regulatory environments.

NN Group itself is the greatest impediment to unlocking the valuation discount

Notwithstanding the above, the reason for publishing our presentation today is our strong belief that one of the key impediments to unlocking NN Group’s valuation discount lies in the Company’s own inability to articulate its case to investors with clarity or conviction. For years, NN Group has traded well below its intrinsic value, and more recently, poorly relative to its peers when it should in fact trade at a premium. This suggests a deep disconnect between the robustness of the business and market perceptions. In a recent shareholder survey, we found a vast majority (>75% of respondents) did not understand NN Group’s interest-rate exposure, while >65% did not understand the Company’s progressive dividend policy. A further >75% majority expressed support for increased asset optimisation, while >85% of participants did not understand why NN Group is present in various countries within the Insurance Europe business, and would support a strategic review. Notably, NN Group management has responded that it is either “difficult to say” or “difficult to predict” in response to analysts’ questions on recent investor calls far more frequently than its European insurance peers.1 Investors and other market participants are left confused, struggling to understand NN Group’s fundamental business qualities, and unable to appreciate its balance sheet strengths and underlying cash-flow generation capabilities. In short, there are compelling fundamentals as well as a vast array of value-creation levers at the Company’s disposal that NN Group has failed to properly set out and explain.

This lack of transparency and insufficient disclosure around fundamentals such as NN Group’s interest rate exposure comes at a significant price: it has led the market to assign a material discount to NN Group’s share price, which is unwarranted in Elliott’s view. In May 2020, management successfully executed a longevity swap transaction that generated significant surplus capital (more than EUR 1.2 billion or approximately 15% of the Company’s market value). Despite the substantial value-accretion potential, management failed to provide any specific and clear guidance on potential uses of the surplus release, leaving the Company bereft of any material share price outperformance.

The CMD imperative

Elliott believes NN Group’s upcoming Capital Markets Day (“CMD”) on 24 June provides an opportune moment for management to address its persistent undervaluation and growing investor discontent. Elliott believes this year’s CMD is the time for NN Group to hold itself accountable, reset its trajectory and communicate not only the basic fundamentals of the business but the many optimisation levers available to unlock the Company’s significant potential. In Elliott’s view, these levers include both sustainable cash-generation measures and extraordinary capital release events, as identified below2:

  1. Asset optimisation: NN Group has one of the lowest risk asset portfolios of any life entity in the European insurance sector. This gives NN Group the opportunity to take advantage of market dislocations and to increase its exposure to private assets, with an opportunity to sustainably increase cash flows by EUR 175 million.
  2. Dutch market leadership: With the acquisition of Delta Lloyd and VIVAT complete, NN Group has become the undisputed No. 1 insurance provider in the Netherlands. Achieving best-in-class operational efficiency across the Company’s Dutch operations would drive incremental value for all stakeholders.
  3. Capital optimisation: Using longevity hedging as an ongoing tool for risk management reduces balance sheet volatility, accelerates capital release and should reduce the Company’s cost of capital. NN Group has ample capacity to enter into more longevity swap transactions and could generate surplus capital of up to EUR 1.9 billion.
  4. Footprint optimisation: NN Group’s large collection of disparate standalone businesses are ripe for rationalisation – operational improvements, reinsurance transactions and outright business sales could generate substantial value for the Company’s shareholders. We believe that optimising Insurance Europe and NN Japan could see the release of more than EUR 2.5 billion of capital.

In summary, the CMD offers NN Group the opportunity to highlight its underappreciated strengths, showcase its robust financial profile, set itself ambitious but achievable cash generation, capital release and capital return targets that collectively demonstrate confidence and conviction in the business, and most importantly, show a willingness to be held accountable for the Company’s future development. Given the Company’s strengths and prospects, there is no reason in our view why NN Group cannot be a standout performer.

Share price upside potential >80%

Elliott believes if NN Group were to adopt these recommendations, it would offer a pathway forward to a materially higher share price – with upside potential of over 80% in the next few years – and the opportunity to establish itself as the leading steward of shareholder capital in the European insurance sector. Furthermore, we believe these measures could more than double total recurring capital return per share to over EUR 6.5 by 2024. Such a result would not only boost NN Group’s market value, but also boost the reputation of NN Group’s management and entire team for showing strong leadership at a time of wider market uncertainty. NN Group would finally – and rightly – be recognised and rewarded as one of the most attractive and differentiated insurance investments in Europe.

Elliott today launched a new website, www.TheTimeisNowforNNGroup.com , where the presentation is available to view and download in full. Interested parties are encouraged to visit the website to receive additional information and to sign up for future updates.

About Elliott

Elliott Management Corporation manages approximately $40.2 billion of assets. Its flagship fund, Elliott Associates, L.P., was founded in 1977, making it one of the oldest funds of its kind under continuous management. The Elliott funds’ investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, and employees of the firm. Elliott Advisors (UK) Limited is an affiliate of Elliott Management Corporation.

Disclaimer

This document has been issued by Elliott Advisors (UK) Limited (“Elliott”), which is authorised and regulated by the United Kingdom’s Financial Conduct Authority (“FCA”). Nothing within this document is intended to promote, and should not be construed as promoting, any funds advised directly or indirectly by Elliott (the "Elliott Funds").

The information herein is confidential and proprietary, and may not be disclosed by, or on behalf of, any recipient to any third party, except with the prior written consent of Elliott.

The material contained herein is for informational purposes only, and does not constitute (a) an offer or invitation to buy or sell, or a solicitation of an offer to buy or sell, any security or other financial instrument and no legal relations shall be created by its issue, (b) a “financial promotion” for the purposes of the Financial Services and Markets Act 2000, (c) “investment research” as defined by the FCA Handbook, or (d) an “investment recommendation” as defined by Regulation (EU) No 596/2014. No information contained herein should be construed as a recommendation by Elliott. This document is not intended to form a basis of any investment decision or as suggesting an investment strategy or as representing any opinion as to the present or future value of any financial instrument.

Elliott has not necessarily sought or obtained the consent from any third party to the use of any statements or information which are described as having been obtained or derived from statements made or published by third parties and this document is not a complete summary of such statements or information. Any such statements or information should not be viewed as indicating the support of such third party for the views expressed in the document.

None of Elliott or any of its directors, officers, employees, agents or advisers ("Elliott Persons") make any representation, warranty or guarantee, express or implied, and no responsibility or liability or duty of care is or will be accepted by the Elliott Persons concerning:

(i) This document and its contents, including whether the information (which may include information and statistics obtained from third party sources) and opinions are accurate, fair, complete or current; and

(ii) The provision of any further information, whether by way of update to the information and opinions contained in this document or otherwise to the recipient after the date of this document.

The information in this document is provided “as is,” is subject to change at any time, and Elliott has no duty to provide any recipient with notice of such changes, nor indeed is it obliged to undertake any changes.

Where the information relates to legislative initiatives, it represents a non-exhaustive summary of Elliott’s current understanding of the legislation and the proposed timeframes as at the date of this publication, which is subject to change pending further clarification of the rules through the legislative rule making and implementation processes in the relevant jurisdiction.

The information in this document is not intended to constitute nor should it be construed as advice of any kind, whether in relation to legal, compliance, accounting, regulatory matters or otherwise. The recipient should discuss with its professional legal, accounting, tax, or other adviser how it may be affected by the information herein and make its own assessment.

The Elliott Funds may have a direct or indirect interest one or more of the companies mentioned herein. Accordingly, this document should not be viewed as impartial and Elliott may have conflicts of interest. Nothing in this document should be taken as any indication of Elliott’s current or future trading or voting intentions, which Elliott may change at any time.

To the fullest extent permitted by law, none of the Elliott Persons will be responsible or liable for any losses, whether direct, indirect or consequential, including loss of profits, damages, costs, claims or expenses, relating to or arising from the recipient's or any person's reliance upon any part of this document. This shall not exclude or limit any liability for or remedy in respect of fraud.

Elliott is not acting for or on behalf of any recipient of this document. The receipt of this document is not to be construed as the giving of investment advice by Elliott to the recipient or to constitute any person a client of Elliott. Elliott is not responsible to any person for providing advice in relation to the subject matter of this document. Before determining on any course of action, the recipient should consult with its independent advisors to review and consider any associated risks and consequences. This document has been prepared without regard to the specific investment objectives, financial situation and needs of any particular recipient. Elliott does not render any opinion regarding legal, accounting, regulatory or tax matters.

Elliott intends to review its investments in the Company on a continuing basis and depending upon various factors, including without limitation, the Company’s financial position and strategic direction, the outcome of any discussions with the Company, overall market conditions, other investment opportunities available to Elliott, and the availability of Company securities at prices that would make the purchase or sale of Company securities desirable. Elliott may at any point in time (in the open market or in private transactions, including in the short term and since the inception of Elliott’s position) buy, sell, cover, hedge or otherwise change the form or substance of any of its investments (including any or all Company securities or related financial instruments) to any degree in any manner permitted by law and expressly disclaims any obligation to notify others of any such changes. Elliott also reserves its right to take any actions with respect to its investments in the Company as it may deem appropriate.


1 Elliott has undertaken a statistical word-count analysis of more than 1.2 million words to compare NN Group’s communications on recent investor calls to those of other European insurance providers.
2 (a)-(b) Sustainable cash-generation measures; (c)-(d) Extraordinary capital release events.

Contact information

London
Sarah Rajani CFA
Elliott Advisors (UK) Limited
T. +44 (0)20 3009 1475
srajani@elliottadvisors.co.uk

Netherlands
Clemens Sassen
Huijskens Communications
T. +31 (0)20 6855 955 / M. +31 (0)6 46 1111 89
clemens@huijskens.nl

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Provides Updates on Its Pharmacokinetic-guided Prophylaxis Studies at ISTH 2020, Reinforcing Its Commitment to Advancing Personalized Care for People with Bleeding Disorders12.7.2020 15:30:00 EESTPress release

Takeda Pharmaceutical Company Limited (“Takeda”) (TSE: 4502/NYSE:TAK) today announced that 13 abstracts are being presented from the company’s Hematology portfolio and pipeline at the International Society on Thrombosis and Haemostasis 2020 Virtual Congress (ISTH 2020). Among the data, Takeda spotlighted four abstracts to highlight its commitment to advancing personalized care through pharmacokinetic (PK)-guided prophylaxis in people living with hemophilia or von Willebrand Disease (VWD) – including scientific updates in patients with hemophilia A from the Phase 3 PROPEL and Phase 3b CONTINUATION studies investigating potential benefits of personalized TAK-660 (rurioctocog alfa pegol) prophylaxis. Two population studies into the PK/pharmacodynamic (PD) profiles of recombinant von Willebrand factor (rVWF), which provide data to assist in the optimization of rVWF personalized dosing strategies, were also presented. Takeda addresses the unique needs of each patient with personalized care

VR Fitness Developer FitXR Secures $7.5 Million In Series A Venture Round Led by Hiro Capital10.7.2020 09:00:00 EESTPress release

FitXR, the leading VR fitness company, today announces that it has secured $6.3m in investment funding, led by Hiro Capital, with continued support from U.S.-based BoostVC, Maveron and TenOneTen Ventures, together with an additional $1.2m in the form of an innovation loan, from Innovate UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200709005856/en/ Cherry Freeman, Co-Founding Partner, Hiro Capital (Photo: Business Wire) FitXR, who had previously secured $1.25 million in seed funding from investors, will use the new investment to expand its operations in Europe and North America, and to accelerate launch of several exciting new products and services for people to keep fit in Virtual Reality. The investment marks a significant show of belief in FitXR, who over the last year has grown to become one of the leaders of the VR fitness sector, with its mission to put the fun back into fitness. Its first product, the boxing rhyt

Laboratory Studies Confirm BETADINE® Antiseptic Products’ Effectiveness Against COVID-19 Virus10.7.2020 01:37:00 EESTPress release

Mundipharma today announced that laboratory testing at the Duke-NUS Medical School in Singapore, has confirmed the effectiveness of its BETADINE® antiseptic products against the novel coronavirus (SARS-CoV-2) which causes COVID-19 disease. Testing has demonstrated BETADINE’s® strong in-vitro virucidal activity, killing 99.99% of the SARS-CoV-2 virus in 30 seconds. The products subjected to testing were: BETADINE® antiseptic products, namely Solution (10% PVP-I), Skin Cleanser (7.5% PVP-I), Gargle and Mouthwash (1.0% PVP-I) and Throat Spray (0.45% PVP-I). The research has been published in the respected Infectious Disease and Therapy Journal on 08 July 2020. “These results confirm our view that BETADINE® antiseptic products, used appropriately and in conjunction with other preventative treatment options including PPE, can play a role in limiting the spread of infections, including COVID-19,” said Raman Singh, CEO Mundipharma. “It also provides the medical community as well as consumers

New Evidence Shows Morinaga Milk’s Probiotic Bifidobacterium breve A1 Improves Memory of Older Adults With Cognitive Dysfunction9.7.2020 21:00:00 EESTPress release

Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company and a key global probiotics manufacturer, confirmed that its proprietary probiotic strain Bifidobacterium breve A1 (a.k.a. B. breve MCC1274) is safe and effective for improving memory functions of older adults with suspected mild cognitive impairment (MCI) in a randomized, double-blind, placebo-controlled trial (RCT). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200709005032/en/ Figure 1. Changes of RBANS scores at 16 weeks from baseline. Values are indicated as mean with error bars as the standard error. **p<0.001, ***p<0.0001, inter-group difference, Student’s t-test. (Graphic: Business Wire) The new study, published recently in the Journal of Alzheimer’s Disease, has produced breakthrough results uncovering a novel promising probiotic intervention for early dementia prevention. The clinical study conducted by a clinical research orga

rf IDEAS and Ricoh Simplify Secure Access to Multifunction Printers9.7.2020 19:05:00 EESTPress release

rf IDEAS, a leading manufacturer of credential readers for authentication and logical access, today announced with Ricoh the integration of its WAVE ID® Plus dual-frequency card reader technology with Ricoh’s Smart Operation Panel (SOP), Gen 2.5. The new WAVE ID Ricoh Universal SOP Reader is the most innovative reader for secure pull-print applications with Ricoh multifunction printers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200709005764/en/ WAVE ID® Ricoh Universal SOP Reader (Photo: Business Wire) rf IDEAS and Ricoh have a proven record of working together to deliver secure workplace solutions that feature the most advanced identification and authentication capabilities. “As we continue our worldwide partnership with a leader in the print industry, we are delighted that Ricoh chose rf IDEAS to develop an innovative credential reader design that connects to its A3 multifunction devices,” said Tod Besse, senior vice

Immersive Labs Adds Tenable Co-Founder and Security Industry Veteran Jack Huffard to its Board of Directors as Demand for Improving and Measuring Cyber Talent Grows9.7.2020 18:46:00 EESTPress release

Immersive Labs, the company empowering organizations to equip, exercise, and evidence human cyber capabilities, announced Jack Huffard, a co-founder and board member of Tenable (Nasdaq: TENB) will join its board of directors to help drive growth. This comes on the heels of Immersive Labs’ recent expansion into the U.S. market, backed by Goldman Sachs and Summit Partners with $50M in financing, after four successful years of fast-growth and an impressive customer roster in the UK and the U.S. With the addition of Huffard to the board, a cybersecurity industry business leader who helped Tenable through its fast growth and successful IPO, the Immersive Labs team is well-suited for its next phase of innovation and market leadership. Huffard also currently serves as a board director for Norfolk Southern Corporation (NYSE: NSC) and is a member of the National Security Telecommunications Advisory Committee (NSTAC), helping the US government navigate pressing national security issues and stren

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom